

### **General structure and length**

The abstracts will be limited to 4000 characters (including spaces but without title, names and affiliations) and the abstracts will be considered “incomplete” if the limit is exceeded.

The abstracts have to be structured by Background / Methods / Results / Discussion and Conclusion.

Abstract on CNS manifestation, endothelium-thrombophilia and BD in pediatric age are strongly encouraged due to the clinical foci of the conference.

### **Use of Product Names**

The non-proprietary (generic/scientific) name can be used in your abstract(s). The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA or EMEA approval, only the non-proprietary name may be used in the title and abstract. Failure to follow this rule will result in disqualification of your submission.

**Further details on abstract submission and selection are found at the submission site which can be accessed after registration**